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1. Introduction 
Earlier investigations aiming at the elucidation of 
the relationship between the chemical structure and 
melanocyte-stimulating activity of a-melanotropin 
have led to the conclusion that the His-Phe-Arg-Trp 
amino acid sequence, occupying positions 6-9 in the 
hormone, possesses all qualitative properties necessary 
to elicit the specific biological activity [ 1 ] . 
Ac-Ser-Tyr-Ser-Met-Glu-His-Phe- 
Arg-Trp-Gly-Lys-Pro-Val-NH2 
a-Melanotropin 
Recently, Eberle and Schwyzer described the 
melanocyte-stimulating activity of the C-terminal 
tripeptide of the hormone, thus demonstrating the 
presence of two independent ‘message sequences’ 
in the polypeptide molecule [2]. 
In the course of a study on the biological properties 
of smaller synthetic tielanotropin fragments, we 
found that not only the two peptides mentioned 
above, but a number of other partial sequences 
possess melanocyte-stimulating activity. Furtherinore, 
naturally occurring peptides, such as enkephalins 
[3] and their fragments also exhibit a significant level 
of melanotropic potency. These unexpected findings 
make necessary a revision of the previous concept of 
specific hormone receptors and hormone active centers, 
at least as far as melanocyte-stimulating peptides are 
concerned. 
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2. Materials and methods 
a-Melanotropin, enkephalins and their fragments 
were synthesized by the classical routes in this 
laboratory. Detailed account of these syntheses will 
appear elsewhere. All substances were checked for 
purity by chromatographic and electrophoretic 
methods, as well as by elemental and amino acid 
analysis. 
Melanocyte-stimulating activity was determined 
by the in vitro frog skin assay developed by Shizume 
et al. [4] , with slight modifications, using a Specol 
spectrophotometer with reflectometric accessories. 
Although Rana pipiens is commonly used as the test 
animal in the in vitro testing of MSH-activities, under 
our laboratory conditions Rana esculenta also proved 
to be suitable, giving, within the limits of error, the 
same activity values for a number of peptides as 
found in other laboratories. These data are also 
shown in table 1. 
3. Results and discussion 
The concept of the active centre or active sites in a 
polypeptide hormone is based mainly on the assump- 
tion that there must be a minimal sequence possessing 
the chemical and conformational features necessary 
to evoke a specific stimulus on the hypothetical 
hormone receptor. This sequence+ a Fragment of the 
whole hormone, should have a definite biological 
activity, which is qualitatively similar to that of the 
parent compound. This activity, sometimes only one- 
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Peptide 
MSH-units/mm01 
Literature Determined in
this laboratory 
cu-Melanotropin 
H-His-Phe-Arg-Trp-OH 
H-Glu-His-Phe-Arg-Trp-Gly-OH 
Ac-Lys-Pro-Val-NH, 
H-Ser-Tyr-Ser-Met-OMe 
H-Glu-His-Pie-OH 
H-Arg-Trp-Gly-OMe 
H-Lys-Pro-Val-NH, 
H-Glu-His-Phe-Lys-Pro-Val-NH, 
millionth of that of the whole molecule, is enlarged 
by several orders of magnitude when this fragment is 
covalently combined with the rest of the molecule 
called binding sequences, reaching the highest potency 
in the complete molecule possessing the optimal 
structural features. 
On the basis of this concept, two independent 
active sites have been postulated in a-melanotropin 
[2], as both the His-Phe-Arg-Trp tetrapeptide 
and the Lys-Pro-Val tripeptide are capable of 
producing melanine dispersion in the isolated frog 
skin. According to our present knowledge this would 
involve the existence of two adequate structure 
recognition sites on the melanotropin receptor. 
This picture is, however, greatly complicated by 
our finding that not only the His-Phe-Arg-Trp and 
Lys-Pro-Val sequences, but also the N-terminal 
Ser-Tyr-Ser-Met tetrapeptide has a melanocyte- 
stimulating activity of its own. Furthermore, the 
Glu-His-Phe-Arg-Trp-Gly hexapeptide, believed 
to be biologically active only with the Phe-Arg 
bond being intact, could be separated into two active 
parts: the Glu-His-Phe and Arg-Trp-Gly tripeptides 
exhibit a melanocyte-stimulating potency of about 
the same magnitude as the active-site peptides 
mentioned previously (table 1). 
That the recognition of a melanocyte-stimulating 
peptide by the melanocyte receptor, cr in general, the 
melanotropic activity of low molecular weight peptides 
has to be explained on a different basis, is supported 
by some further observations. Thus enkephalins, 
naturally occurring peptides with potent opiate agonist 
activity, isolated recently from pig brain [3] showed 
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3.10’ 121 
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a melanocyte-stimulating potency, which was com- 
parable with that of the Glu-His-Phe-Arg-Trp-Gly 
hexapeptide derived from c\-melanotropin. Further- 
more, fragments of enkephalins, such as the Tyr-Gly- 
Gly 
H-Tyr-Gly-Gly-Phe-Leu-OH 
H-Tyr-Gly-Gly-Phe-Met-OH 
Enkephalins 
and Phe-Met sequences also proved to be active in 
the in vitro test, although their melanocyte-stimulating 
potency was smaller, and corresponded to the activity 
of the MSH tri- and tetrapeptides. These results are 
summarized in table 2. 
In order to test whether these independently active 
small peptides are capable of producing higher 
biological activity in a cooperative manner when com- 
bined covalently, two derivatives were examined. The 
H-Glu-His-Phe-Lys-Pro-Val-NH2 hexapeptide 
containing two low-acting melanotropin sequences had 
a melanocyte-stimulating activity (1 *lo5 U/mmol), 
Table 2 
Peptide 
H-Tyr-Gly-Gly-Phe-Met-OMe 
H-Tyr-Gly-Gly-Phe-Leu-OH 
H-Tyr-Gly-Gly-OH 
H-Phe-Met-OMe 
H-Tyr-Gly-Gly-Lys-Pro-Val-NH, 
MSH-units/mm01 
5 . 105 
2.5 . lo5 
2, lo4 
1.10’ 
5 * lo5 
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which was higher than that of either of the components 
(table 1); the H-Tyr-Gly-Gly-Lys-Pro-Val-NH2 
hexapeptide, being the combination of an enkephalin 
and a melanotropin sequence, also proved to be more 
active than the constituting tripeptides (table 2). 
It is fairly difficult to reach an unequivocal con- 
clusion explaining the similar biological activity of a 
series of structurally unrelated peptides. Obviously, the 
qualification as an active site of the His-Phe-Arg-Trp 
or Lys-Pro-Val sequences may equally be attributed 
to other parts of the molecule. It is likely that a 
molecule possessing continuously rising biological 
potency can be built up from any of the active 
fragments, reaching the maximal activity in the intact 
a-melanotropin. 
The fact that in a-melanotropin there are not 
only one or two, but at least four, and in other amino 
acid combinations possibly more ‘active sites’, can be 
explained in several ways. It is possible, for example, 
that the melanocyte-receptor does not possess any 
specific hormone recognizing region or, at least, this 
site is of a very limited specificity. In consequence, the 
receptor may interact with different peptides which 
are not structurally related to each other. As long as 
these peptides are.small, they are bound to this 
nonspecific site loosely, and in order to get a 
reasonable amount of productive complexes and a 
measurable biological effect, an extremely high 
(up to 0.1 mmol) peptide concentration is necessary. 
With the growing complexity of the structure, a 
multiple-point attachment to the receptor through 
the (in themselves imilarly nonspecific) peptide 
sequences can be attained, leading to a more stable 
complex with a higher specific activity. Finally, the 
optimal structure of the whole hormone, which 
corresponds the best to the adjacent binding sites 
on the receptor will result in the formation of the 
most productive hormone-receptor complex, 
accompanied by the highest biological potency. In 
other words, the intact hormone is a highly effective 
combination of low-specificity peptide parts, none 
of them playing a distinguished functional role. 
It is also conceivable that while a-melanotropin 
initiates the series of events leading to the melanine 
dispersion by reacting with the receptor in a highly 
specific manner, the small hormone fragments and 
peptides not related to a-melanotropin interact 
with other, less specific sites. Then, of course, the 
question arises, which are the structural features 
necessary to distinguish between receptor sites of 
different specificity. 
Finally, the possibility must not be left out of 
consideration that the effect of small peptides may 
manifest itself by some other mechanism than acting 
on the melanocyte receptor; melanine dispersion can 
also be produced by influencing other phases of this 
multistep process, such as inhibition of cyclic AMP 
degradation, alteration of ionic environment, etc. 
In this case, penetration of the small peptide into the 
inside of the cell has to be assumed, which might be 
the result of the high peptide concentration applied, 
approaching sometimes the ion concentration of the 
Ringer solution used in the in vitro experiments. Such 
a high peptide concentration, quite unusual in 
physiological conditions, may bring about melanocyte 
stimulation even by a nonspecific physical alteration of 
the membrane structure. 
Further experiments are required to decide which 
of the possible mechanisms is responsible for the 
melanocyte-stimulating activity of these small peptides. 
It would also be worthwhile to investigate whether 
this phenomenon is restricted only to melanine disper- 
sion, or can be found in the case of other peptide 
hormone actions. 
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